Management

John Kollins

President & CEO

Prior to cofounding Satsuma Pharmaceuticals in 2016, John was founder and Managing Director of Parnassus Advisors, LLC, where he provided strategy and business / corporate development services to biopharmaceutical companies.  Since entering the biopharmaceutical industry in 1989, John has served in C-level and senior executive roles in multiple public and private biopharmaceutical companies, including Transcept Pharmaceuticals, OXiGENE, CovX, Renovis, Athena Neurosciences / Elan Pharmaceuticals, and Immunex.  John earned an MBA from the University of Virginia’s Darden School and an engineering degree from Duke University.

Detlef Albrecht, MD

Chief Medical Officer

Prior to joining Satsuma Pharmaceuticals, Detlef served in C-level and senior executive roles in multiple public and private biopharmaceutical companies, including Armetheon, Sorbent, Relypsa, Ilypsa, ALZA, Miravant and Schwarz Pharma.  Since entering the biopharmaceutical industry in 1992, Detlef has been involved with the development of drugs for various indications in the areas of urology, pain management, oncology, renal and cardiovascular diseases. Detlef received his medical degree and doctorate from the Rheinisch Westfälische Technische Hochschule in Aachen, Germany.

Tom O’Neil

Chief Financial Officer

Prior to joining Satsuma Pharmaceuticals, Tom was Chief Financial Officer at Protagonist Therapeutics, Inc.  Since entering the biopharmaceutical industry in 1999, Tom has served in C-level and other management roles in multiple public and private biopharmaceutical companies, including Arcadia Biosciences, Sorbent Therapeutics, ChemGenex Pharmaceuticals, Nodality, and Monogram Biosciences.  Tom earned an MBA from the University of California Los Angeles’ Anderson Graduate School of Management and a BA from Pomona College.

Mic Iwashima

Vice President & Head of Operations

Prior to joining Satsuma Pharmaceuticals, Mic served since 2002 in a variety of management roles at Shin Nippon Biomedical Laboratories.  Mic has an extensive background in nasal drug delivery, with 15 years of experience developing SNBL’s nasal drug delivery platform technology and product candidates.  His roles at SNBL have encompassed operations, product development, regulatory affairs, business development and intellectual property management.  Mic earned an engineering degree from North Carolina State University, where he also did research in the area of nasal flow computational fluid dynamics.

Robert Schultz

Vice President & Head of CMC

Prior to joining Satsuma Pharmaceuticals, Rob was an early member of the senior leadership team at Pearl Therapeutics (acquired by AstraZeneca), where he led CMC and global project teams developing Pearl’s metered-dose inhaler (MDI) products, including Bevespi Aerosphere and Pearl’s triple combination MDI.  Since entering the pharmaceutical industry in 1989, Rob has also led CMC development initiatives for multiple other inhalation products, including Advair, Serevent, Flovent, Ventolin, Azmacort, and an insulin MDI product, while serving in roles of increasing responsibility at GlaxoSmithKline and at Kos (acquired by Abbott).  Rob earned his biochemistry degree from Dartmouth College.

Shannon Strom, Ph.D., R.A.C.

Vice President & Head of Regulatory Affairs

Prior to joining Satsuma Pharmaceuticals in 2018, Shannon was a member of the global regulatory leadership and drug development teams at Pearl Therapeutics (acquired by AstraZeneca), which developed multiple metered-dose inhaler (MDI) products, including Bevespi Aerosphere and Pearl’s triple combination MDI.  Most recently, she worked in a global regulatory role at Roivant Sciences.  Since beginning her biopharmaceutical industry career in 2005, Shannon has been involved with the development of drugs for various indications in the areas of neurology, psychiatry, pain management, oncology, and respiratory disease. Shannon earned an undergraduate degree in biology from Duke University and a doctorate degree in pharmacology from the University of North Carolina.